<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />



<meta name="date" content="2026-02-13" />

<title>SYNCOMF</title>

<script src="rmdlib/header-attrs-2.30/header-attrs.js"></script>
<script src="rmdlib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="rmdlib/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="rmdlib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="rmdlib/navigation-1.1/tabsets.js"></script>
<script src="rmdlib/accessible-code-block-0.0.1/empty-anchor.js"></script>
<link href="rmdlib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="rmdlib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<meta name="description" content="Indian equities analysis, margin reports, risk, etc..." />
<meta property="og:image" content="https://avatars3.githubusercontent.com/u/21966469?s=400&v=4" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>










<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">StockViz</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-globe"></span>
     
    Macro
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-bnd.html">Fixed Income</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cur.html">Currencies</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cmdy.html">Commodities</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-arrows-v"></span>
     
    52w H&amp;L
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-rocket"></span>
     
    ATH
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-magnet"></span>
     
    Drawdowns
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-train"></span>
     
    Streaks
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-hand-pointer-o"></span>
     
    Indian Indices
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-risk.html">Performance Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-IN.html">Index Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-MKT-CAP.html">Classification Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-industry.html">Industry Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-syn.html">Synthetic Indices</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-vol-NIFTY.html">NIFTY Volatility</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-valuations.html">Valuations</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/results-IN.html">Result Dates</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/eq-in/rp-margin.html">Margin Report</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-shopping-bag"></span>
     
    Funds
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports03/mf/rp-IN.html">Indian Mutual Funds</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports03/pms/rp-IN.html">Indian PMS</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-risk.html">US ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-sector.html">US Sector ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-country.html">Country $ ETFs</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-percent"></span>
     
    Fama-French
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-industry.html">Industry</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-factors.html">Factors</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-regression.html">Regressions</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https://stockviz.biz">
    <span class="fa fa-home"></span>
     
  </a>
</li>
<li>
  <a href="https://stockviz.substack.com">
    <span class="fa fa-envelope-o"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">SYNCOMF</h1>
<h3 class="subtitle">Equity Metrics</h3>
<h4 class="date">February 13, 2026</h4>

</div>


<div id="syncom-formulations-india-limited" class="section level1">
<h1>Syncom Formulations (India) Limited</h1>
<p><a href="/reports01/index/industry/rp-Pharmaceuticals.html">Pharmaceuticals</a></p>
<div id="annual-returns" class="section level2">
<h2>Annual Returns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SYNCOMF.fan.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SYNCOMF.annret.png" /></p>
</div>
<div id="cumulative-returns-and-drawdowns" class="section level2">
<h2>Cumulative Returns and Drawdowns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SYNCOMF.cumret.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SYNCOMF.sma.cumret.png" /></p>
<p><br><br></p>
</div>
<div id="fundamentals" class="section level2">
<h2>Fundamentals</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SYNCOMF.eps.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SYNCOMF.RevenueFromOperations.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SYNCOMF.ebit.png" /></p>
<p><br><br></p>
</div>
<div id="ownership" class="section level2">
<h2>Ownership</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SYNCOMF.ownership.png" /></p>
<p><br><br></p>
</div>
<div id="margined" class="section level2">
<h2>Margined</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SYNCOMF.mtf.png" /></p>
<p><br><br></p>
<p><br />
</p>
</div>
<div id="ai-summary" class="section level2">
<h2>AI Summary</h2>
<p><em>asof: 2025-12-08 </em></p>
<div id="syncom-formulations-india-limited-syncomf-investor-analysis-as-of-q2-fy2026" class="section level9">
<p class="heading"><strong>SYNCOM FORMULATIONS (INDIA) LIMITED (SYNCOMF) ‚Äì Investor Analysis (as of Q2 FY2026)</strong></p>
<p><em>Based on Unaudited Financial Results for Q2 &amp; H1 FY2026 (ended 30th September 2025) and Subsequent Corporate Developments</em></p>
<hr />
</div>
<div id="business-overview" class="section level6">
<h6><strong>1. Business Overview</strong></h6>
<p>Syncom Formulations (India) Limited is a publicly traded pharmaceutical company engaged primarily in: - <strong>Pharmaceutical Drugs &amp; Formulations</strong> (core business), - <strong>Trading of Commodities</strong>, and - <strong>Renting of Property</strong> (real estate assets).</p>
<p>The company has three wholly-owned subsidiaries: <em>Synmex Pharma</em>, <em>Sante Biotech</em>, and <em>Vincit Biotech International Pvt. Ltd.</em></p>
<p>It operates manufacturing facilities in Pithampur (Madhya Pradesh), with corporate offices in Mumbai.</p>
<hr />
</div>
<div id="key-financial-highlights-q2-h1-fy2026" class="section level6">
<h6><strong>2. Key Financial Highlights (Q2 &amp; H1 FY2026)</strong></h6>
<table>
<thead>
<tr class="header">
<th>Metric</th>
<th>Q2 FY2026 (‚ÇπL)</th>
<th>Q2 FY2025 (‚ÇπL)</th>
<th>YoY Growth</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Standalone Revenue from Operations</strong></td>
<td>12,143.5</td>
<td>10,149.3</td>
<td>+19.6%</td>
</tr>
<tr class="even">
<td><strong>Net Profit (Standalone)</strong></td>
<td>1,684.1</td>
<td>1,095.0</td>
<td>+53.8%</td>
</tr>
<tr class="odd">
<td><strong>Net Profit Margin (Standalone)</strong></td>
<td>13.3%</td>
<td>10.8%</td>
<td>‚Üë +250 bps</td>
</tr>
<tr class="even">
<td><strong>EPS (Basic, Diluted)</strong></td>
<td>‚Çπ0.18</td>
<td>‚Çπ0.16</td>
<td>+12.5%</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr class="header">
<th>Metric</th>
<th>H1 FY2026 (‚ÇπL)</th>
<th>H1 FY2025 (‚ÇπL)</th>
<th>YoY Growth</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Revenue from Operations</strong></td>
<td>23,798.2</td>
<td>18,735.7</td>
<td>+27.0%</td>
</tr>
<tr class="even">
<td><strong>Net Profit</strong></td>
<td>3,257.0</td>
<td>1,857.9</td>
<td>+75.3%</td>
</tr>
<tr class="odd">
<td><strong>Net Profit Margin (H1)</strong></td>
<td>13.7%</td>
<td>9.9%</td>
<td>‚Üë +380 bps</td>
</tr>
</tbody>
</table>
<blockquote>
<p><strong>Note</strong>: All amounts in Lakhs (‚ÇπL). Consolidated numbers show similar trends.</p>
</blockquote>
<hr />
</div>
<div id="tailwinds-growth-drivers" class="section level6">
<h6><strong>3. Tailwinds (Growth Drivers)</strong></h6>
<div id="strong-revenue-growth" class="section level9">
<p class="heading">üîπ 1. <strong>Strong Revenue Growth</strong></p>
<ul>
<li><strong>Revenue (operations)</strong> grew <strong>27% YoY in H1</strong>, driven by pharmaceuticals.</li>
<li>Pharmaceutical segment revenue up to ‚Çπ24,630L from ‚Çπ18,803L (YoY +30.7%), indicating <strong>strong demand and market share gains</strong>.</li>
<li>Pricing power and/or volume growth likely in core pharma business.</li>
</ul>
</div>
<div id="operating-leverage-margin-expansion" class="section level9">
<p class="heading">üîπ 2. <strong>Operating Leverage &amp; Margin Expansion</strong></p>
<ul>
<li>Despite rising raw material costs (<strong>Cost of Materials: 84% of total expenses</strong>), the company <strong>expanded net margins by ~380 basis points</strong> (from 9.9% to 13.7%).</li>
<li>This suggests effective cost control (e.g., inventory management, OpEx optimization) and/or better product mix.</li>
</ul>
</div>
<div id="improved-inventory-turnover" class="section level9">
<p class="heading">üîπ 3. <strong>Improved Inventory Turnover</strong></p>
<ul>
<li><strong>Inventory reduced by ‚Çπ1,283L</strong> from March 2025 to September 2025.</li>
<li>Indicates improved working capital management and faster realization cycles.</li>
</ul>
</div>
<div id="high-cash-flow-generation-from-operations" class="section level9">
<p class="heading">üîπ 4. <strong>High Cash Flow Generation from Operations</strong></p>
<ul>
<li>Net cash from operating activities: <strong>‚Çπ5,568L in H1 FY2026</strong> (vs ‚Çπ2,331L in full FY2025).</li>
<li>Strong operating cash flow supports <strong>debt reduction, reinvestment, and shareholder returns</strong>.</li>
</ul>
</div>
<div id="cash-flow-discipline-debt-reduction" class="section level9">
<p class="heading">üîπ 5. <strong>Cash Flow Discipline &amp; Debt Reduction</strong></p>
<ul>
<li>Net <strong>borrowings reduced by ‚Çπ374L</strong> in H1.</li>
<li>Despite investments in fixed deposits and marketable securities (-‚Çπ5,076L in H1 investing cash flows), cash position remains stable (~‚Çπ23.66L).</li>
<li>Suggests <strong>debt-light, financially conservative strategy</strong>.</li>
</ul>
</div>
<div id="real-estate-investment-rental-income" class="section level9">
<p class="heading">üîπ 6. <strong>Real Estate Investment &amp; Rental Income</strong></p>
<ul>
<li>Owns <strong>investment property worth ‚Çπ4,733L</strong>, generating stable rental income (‚Çπ188.8L in H1).</li>
<li>Rental EBITDA margin: ~93%, indicating <strong>high-margin passive income stream</strong>.</li>
</ul>
<hr />
</div>
</div>
<div id="headwinds-challenges" class="section level6">
<h6><strong>4. Headwinds &amp; Challenges</strong></h6>
<div id="high-cost-of-materials" class="section level9">
<p class="heading">üîª 1. <strong>High Cost of Materials</strong></p>
<ul>
<li><strong>Cost of materials consumed dropped in Q2</strong> (‚Çπ4,642L vs ‚Çπ5,961L in Q1) but remains <strong>38% of total revenue</strong>.</li>
<li>However, <strong>raw material volatility</strong> remains a key risk (especially for APIs and excipients).</li>
</ul>
</div>
<div id="large-working-capital-intensity" class="section level9">
<p class="heading">üîª 2. <strong>Large Working Capital Intensity</strong></p>
<ul>
<li>Despite improvement:
<ul>
<li>High <strong>trade receivables (‚Çπ10,063L)</strong>,</li>
<li>Large <strong>trade and other payables (‚Çπ3,963L consolidated)</strong>.</li>
</ul></li>
<li>Exposure to <strong>micro/small enterprise credit risk</strong> via trade payables (~‚Çπ667L dues to MSEs).</li>
<li>Working capital changes had a favorable impact this quarter ‚Äî this may not be repeatable.</li>
</ul>
</div>
<div id="investment-in-fixed-deposits-securities" class="section level9">
<p class="heading">üîª 3. <strong>Investment in Fixed Deposits &amp; Securities</strong></p>
<ul>
<li><strong>‚Çπ5,076L invested in marketable securities (H1)</strong> ‚Äî reduces idle cash but lowers <strong>ROE on capital deployment</strong> unless high yield.</li>
<li>May indicate <strong>lack of high-return capex opportunities</strong>, limiting growth reinvestment.</li>
</ul>
</div>
<div id="trading-segment-is-shrinking" class="section level9">
<p class="heading">üîª 4. <strong>Trading Segment is Shrinking</strong></p>
<ul>
<li><strong>No revenue in Q2 from commodity trading</strong>.</li>
<li>Previous contribution (~‚Çπ100‚Äì250L) now appears inactive or marginal.</li>
<li>Reduced diversification; focus appears to be <strong>100% on pharma</strong>.</li>
</ul>
<hr />
</div>
</div>
<div id="strategic-developments-acquisition-of-commercial-property" class="section level6">
<h6><strong>5. Strategic Developments: Acquisition of Commercial Property</strong></h6>
<p>On <strong>22nd November 2025</strong>, Syncom acquired the <strong>entire 3rd floor of ‚ÄúTrade Star‚Äù, Andheri (E), Mumbai</strong> for <strong>‚Çπ51.7 Crores (~‚Çπ517L)</strong>.</p>
<div id="implications" class="section level9">
<p class="heading">Implications:</p>
<p>‚úÖ <strong>Tailwinds</strong>: - Adds <strong>prime real estate asset</strong> in Mumbai ‚Äì long-term value creation. - Likely to boost <strong>rental income</strong> and <strong>asset turnover</strong>. - Can serve as <strong>corporate office, R&amp;D, or leased out</strong> ‚Äî enhances capital efficiency.</p>
<p>‚ùå <strong>Risks</strong>: - <strong>Large cash outflow</strong> (~100% of H1 net profit). - Will increase <strong>long-term liabilities</strong> or reduce liquidity. - <strong>Execution risk</strong> in integration, maintenance, and monetization.</p>
<p>‚Üí But given debt-reduction history, likely funded <strong>from surplus cash and cash equivalents</strong> (‚Çπ23L) and <strong>fixed deposits</strong> (‚Çπ1,489L), so <strong>not over-leveraged</strong>.</p>
<hr />
</div>
</div>
<div id="segment-performance-standalone-h1" class="section level6">
<h6><strong>6. Segment Performance (Standalone H1)</strong></h6>
<table>
<thead>
<tr class="header">
<th>Segment</th>
<th>Revenue (‚ÇπL)</th>
<th>YoY Growth</th>
<th>EBITDA (‚ÇπL)</th>
<th>EBITDA Margin</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Pharma (Core)</strong></td>
<td>24,630</td>
<td>+30.7%</td>
<td>4,128</td>
<td>16.8%</td>
</tr>
<tr class="even">
<td><strong>Commodities Trading</strong></td>
<td>105</td>
<td>-73%</td>
<td>1.35</td>
<td>-</td>
</tr>
<tr class="odd">
<td><strong>Property Renting</strong></td>
<td>189</td>
<td>+2.8%</td>
<td>177</td>
<td>93.5%</td>
</tr>
</tbody>
</table>
<blockquote>
<p><strong>Insight</strong>: <strong>Pharma is the real engine</strong> driving earnings. Company may exit or downscale trading business.</p>
</blockquote>
<hr />
</div>
<div id="growth-prospects" class="section level6">
<h6><strong>7. Growth Prospects</strong></h6>
<table>
<colgroup>
<col width="47%" />
<col width="52%" />
</colgroup>
<thead>
<tr class="header">
<th>Opportunity</th>
<th>Assessment</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Expansion in Pharma</strong> (Formulations, NCEs, OTC)</td>
<td>High ‚Äì increased R&amp;D focus via subsidiaries could yield pipeline benefits.</td>
</tr>
<tr class="even">
<td><strong>Rental Income Growth</strong> (New property acquisition)</td>
<td>Medium ‚Äì incremental income, but not scalable.</td>
</tr>
<tr class="odd">
<td><strong>Export Market Penetration</strong></td>
<td>Unknown (no data, but potential in emerging markets)</td>
</tr>
<tr class="even">
<td><strong>Subsidiary Leverage</strong> (Biotech arms ‚Äì Sante, Vincit)</td>
<td>Medium-Long Term ‚Äì potential for biosimilars, specialty drugs.</td>
</tr>
<tr class="odd">
<td><strong>M&amp;A in Pharma Space</strong></td>
<td>Rising ‚Äì recent acquisition shows ambition beyond organic growth.</td>
</tr>
</tbody>
</table>
<blockquote>
<p><strong>Near-Term EPS Growth Outlook</strong>: Strong ‚Äî H1 EPS already 67% of full-year FY2025 (‚Çπ0.57). FY2026 EPS could exceed <strong>‚Çπ0.75</strong> if trend continues.</p>
</blockquote>
<hr />
</div>
<div id="key-risks" class="section level6">
<h6><strong>8. Key Risks</strong></h6>
<table>
<colgroup>
<col width="17%" />
<col width="20%" />
<col width="61%" />
</colgroup>
<thead>
<tr class="header">
<th>Risk</th>
<th>Impact</th>
<th>Mitigation Observed</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Regulatory Risks (Pharma Sector)</strong></td>
<td>High</td>
<td>Compliance focus evident; audits in place</td>
</tr>
<tr class="even">
<td><strong>API Price Volatility &amp; Import Dependence</strong></td>
<td>High</td>
<td>Inventory drop helps; no hedging info</td>
</tr>
<tr class="odd">
<td><strong>Intense Competition (Generics)</strong></td>
<td>Medium-High</td>
<td>Margin expansion suggests differentiation</td>
</tr>
<tr class="even">
<td><strong>Execution Risk in New Acquisitions</strong></td>
<td>Medium</td>
<td>Property bought fully paid ‚Äì limited risk</td>
</tr>
<tr class="odd">
<td><strong>Subsidiary Performances Unreported</strong></td>
<td>Medium</td>
<td>Parent company strong; consolidation clean</td>
</tr>
<tr class="even">
<td><strong>Liquidity Risk Post ‚Çπ51.7Cr Acquisition</strong></td>
<td>Low</td>
<td>Cash flows strong; debt reducing; no credit crunch observed</td>
</tr>
</tbody>
</table>
<hr />
</div>
<div id="valuation-market-position-indicative" class="section level6">
<h6><strong>9. Valuation &amp; Market Position (Indicative)</strong></h6>
<p>As a non-index-heavy pharma stock, Syncom trades with: - Strong <strong>earnings visibility</strong> in H1, - <strong>Low debt</strong>, improving ROE, - Expansion into <strong>strategic real estate</strong>.</p>
<p>If FY2026 EPS reaches <strong>‚Çπ0.75‚Äì0.80</strong>, and stock trades at <strong>20‚Äì25x P/E</strong>, <strong>fair value range: ‚Çπ15‚Äì20/share</strong>. - Current market cap: ~‚Çπ1,770 Crores (94 Cr shares). - Stock currently might be <strong>undervalued</strong> if earnings momentum sustains.</p>
<hr />
</div>
<div id="summary-investment-summary-of-syncomf" class="section level6">
<h6>‚úÖ <strong>Summary: Investment Summary of SYNCOMF</strong></h6>
<table>
<colgroup>
<col width="40%" />
<col width="60%" />
</colgroup>
<thead>
<tr class="header">
<th>Parameter</th>
<th>Assessment</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Growth Trajectory</strong></td>
<td>‚úÖ Strong revenue &amp; profit growth (+27% revenue, +75% net profit H1)</td>
</tr>
<tr class="even">
<td><strong>Operating Efficiency</strong></td>
<td>‚úÖ Margin expansion (‚Üë3.8%), improved inventory</td>
</tr>
<tr class="odd">
<td><strong>Cash Flow Health</strong></td>
<td>‚úÖ Excellent operating cash flow, debt reduction</td>
</tr>
<tr class="even">
<td><strong>Strategic Moves</strong></td>
<td>‚úÖ Acquisition signals confidence and long-term planning</td>
</tr>
<tr class="odd">
<td><strong>Business Focus</strong></td>
<td>‚úÖ Focused on core pharma + stable rentals</td>
</tr>
<tr class="even">
<td><strong>Balance Sheet</strong></td>
<td>‚úÖ Net cash positive, low leverage, strong equity (‚Çπ28,245L)</td>
</tr>
<tr class="odd">
<td><strong>Risks</strong></td>
<td>‚ö†Ô∏è API cost volatility, limited transparency on exports, trading segment decline</td>
</tr>
<tr class="even">
<td><strong>Outlook</strong></td>
<td><strong>POSITIVE</strong> ‚Äì well-positioned for sustained earnings growth; potential multibagger candidate if execution continues</td>
</tr>
</tbody>
</table>
<hr />
</div>
<div id="conclusion-buy-accumulate-recommendation-investor-perspective" class="section level6">
<h6>üîö <strong>Conclusion: ‚ÄúBUY‚Äù / ‚ÄúACCUMULATE‚Äù Recommendation (Investor Perspective)</strong></h6>
<p><strong>SYNCOMF</strong> is demonstrating: - <strong>Robust financial performance</strong>, - <strong>Disciplined capital allocation</strong>, and - <strong>Strategic intent</strong> through asset acquisition.</p>
<p>While not a high-growth biotech innovator, it shows <strong>solid execution in generics + value-add through real estate</strong>.</p>
<p><strong>Ideal for</strong>: Long-term investors seeking stable, profitable pharma plays with conservative management and visible earnings growth.</p>
<blockquote>
<p><strong>Key to watch in future quarters</strong>: - Rental yield from new property, - Progress in subsidiary pipelines, - Export numbers, - Working capital cycle stability.</p>
</blockquote>
<hr />
<p><strong>Last Updated</strong>: November 23, 2025<br />
<strong>Sources</strong>: SYNFQ2 FY2026 Standalone &amp; Consolidated Results, Limited Review Reports (CA), Corporate Disclosure (BSE/NSE) ‚Äì Acquisition Announcement.</p>
</div>
</div>
</div>

&nbsp;
&nbsp;
<hr />
<p style="text-align: center;">Copyright &copy; 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.</p>
<p style="text-align: center;"><a href="https://github.com/stockviz/reports/issues">&#x1F41E;</a></p>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
